Literature DB >> 8262074

Surgical revascularization in the treatment of ventricular tachycardia and fibrillation exposed by exercise-induced ischaemia.

R F Berntsen1, P Gunnes, M Lie, K Rasmussen.   

Abstract

The role of myocardial revascularization in the treatment of malignant ventricular arrhythmias is not well defined. Our hypothesis was that in patients with ventricular tachycardia or fibrillation exposed by exercise-induced ischaemia, the acute transient ischaemia plays a principal causal role, and that in these patients surgical myocardial revascularization alone might be an effective treatment. Among 1100 consecutive patients undergoing isolated coronary artery bypass surgery (CABG) 30 patients (2.7%) characterized by ventricular tachycardia or fibrillation at the symptom-limited exercise tests prior to revascularization were studied prospectively. All patients had exercise-induced angina pectoris or ischaemic ST-segment depression preceding at least one of the arrhythmic events. In addition, eight of these 30 patients had experienced syncope during out-of-hospital exertional activities. After surgical revascularization, the 28 patients surviving to hospital discharge were followed for 1.6 to 86 months (mean 29 +/- 29 months) as outpatients and underwent between one to eight exercise tests (mean 2.6 +/- 1.9). One of these patients died suddenly of unknown causes at 14 months, another from cancer at 53 months. Twenty-six patients experienced a total of 34 episodes of ventricular tachycardia before revascularization. Two of these patients, both having residual ischaemia, had arrhythmia recurrences during follow-up; odds ratio (OR) 84.5, 95% confidence interval (CI) 18.7-381.9; P = < 0.010. Exercise-induced ventricular fibrillation occurred in eight patients pre-operatively.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8262074     DOI: 10.1093/eurheartj/14.10.1297

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  4 in total

1.  2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias.

Authors:  Edmond M Cronin; Frank M Bogun; Philippe Maury; Petr Peichl; Minglong Chen; Narayanan Namboodiri; Luis Aguinaga; Luiz Roberto Leite; Sana M Al-Khatib; Elad Anter; Antonio Berruezo; David J Callans; Mina K Chung; Phillip Cuculich; Andre d'Avila; Barbara J Deal; Paolo Della Bella; Thomas Deneke; Timm-Michael Dickfeld; Claudio Hadid; Haris M Haqqani; G Neal Kay; Rakesh Latchamsetty; Francis Marchlinski; John M Miller; Akihiko Nogami; Akash R Patel; Rajeev Kumar Pathak; Luis C Saenz Morales; Pasquale Santangeli; John L Sapp; Andrea Sarkozy; Kyoko Soejima; William G Stevenson; Usha B Tedrow; Wendy S Tzou; Niraj Varma; Katja Zeppenfeld
Journal:  J Interv Card Electrophysiol       Date:  2020-10       Impact factor: 1.900

2.  2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias.

Authors:  Edmond M Cronin; Frank M Bogun; Philippe Maury; Petr Peichl; Minglong Chen; Narayanan Namboodiri; Luis Aguinaga; Luiz Roberto Leite; Sana M Al-Khatib; Elad Anter; Antonio Berruezo; David J Callans; Mina K Chung; Phillip Cuculich; Andre d'Avila; Barbara J Deal; Paolo Della Bella; Thomas Deneke; Timm-Michael Dickfeld; Claudio Hadid; Haris M Haqqani; G Neal Kay; Rakesh Latchamsetty; Francis Marchlinski; John M Miller; Akihiko Nogami; Akash R Patel; Rajeev Kumar Pathak; Luis C Sáenz Morales; Pasquale Santangeli; John L Sapp; Andrea Sarkozy; Kyoko Soejima; William G Stevenson; Usha B Tedrow; Wendy S Tzou; Niraj Varma; Katja Zeppenfeld
Journal:  Europace       Date:  2019-08-01       Impact factor: 5.214

3.  Cardiac syncope due to transient coronary artery occlusion: the role of percutaneous angioplasty.

Authors:  S Burn; R Schilling; G C Kaye
Journal:  Postgrad Med J       Date:  1998-06       Impact factor: 2.401

4.  Ventricular Tachycardia Associated Syncope in a Patient of Variant Angina without Chest Pain.

Authors:  Soo Jin Kim; Ji Young Juong; Tae-Ho Park
Journal:  Korean Circ J       Date:  2015-12-29       Impact factor: 3.243

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.